Monovalent group A, group C meningococcal vaccines, and a bivalent vaccine for both groups A and C were licensed

,

On Jan. 3, 1978, the U.S. Food and Drug Administration (FDA) licensed the Monovalent group A (Menomune-A by Connaught), group C (Menomune-C by Connaught) meningococcal vaccines, and a bivalent vaccine for both groups A and C (Menomune-A/C by Connaught).

Meningococcal disease is a serious and global life-threatening disease. Six serogroups (A, B, C, W-135, X, and Y) account for the majority of meningococcal disease worldwide.

Tags:


Source: U.S. National Library of Medicine
Credit:

Advertise in our E-history sent to 5,000 plus company decision makers twice per month for only $300 per month. Reserve your space now! E-mail: info@LifeScienceHistory.com.